绿叶制药(02186.HK)盐酸安舒法辛缓释片已于日本提交临床试验申请
格隆汇8月22日丨绿叶制药(02186.HK)公告称,公司连同其附属公司欣然宣布,盐酸安舒法辛缓释片(「LY03005」,用于治疗抑郁症的化学新药,已于日本提交临床试验申请。LY03005是一项基于新型化合物平台开发的中枢神经系统在研产品,该药物是以缓释片形式制备的独家盐酸安舒法辛产品(一种5–羟色胺–去甲肾上腺素–多巴胺三重再摄取抑制剂(SNDRI)),用于治疗抑郁症。
除LY03005外,本集团还有多个中枢神经系统的在研项目,同步在中国及海外市场进行开发,如注射用利培酮缓释微球Rykindo?(LY03004,关于精神分裂症和双向情感障碍)、注射用罗替戈汀缓释微球LY03003(关于帕金森氏症)、帕利哌酮缓释混悬肌肉注射剂LY03010(关于精神分裂症和分裂情感性障碍的治疗)及利期的明透皮多日贴剂LY30410(关于中轻度阿兹海默症)等项目。上述在研产品在中国、美国、欧洲和日本等战略市场注册进展良好,预计未来将在这些国家上市并进一步扩展到全球市场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.